Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study

0 avis

Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study

Archive ouverte

Edité par CCSD ; Elsevier -

International audience

Langue: en

Consulter en ligne

Consulter le document

Suggestions

Du même auteur

Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study

Archive ouverte | Solomon, Benjamin | CCSD

International audience. PURPOSE Lorlatinib improved progression-free survival (PFS) and intracranial activity versus crizotinib in patients with previously untreated, advanced, ALK -positive non–small cell lung canc...

First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer

Archive ouverte | Shaw, Alice | CCSD

International audience

Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial

Archive ouverte | Wu, Yi-Long | CCSD

International audience

Chargement des enrichissements...